Sponsored by Eli Lilly & Company
Date: Wednesday 10 April 2019
Location: Great Hill, BCEC
Prof Peter Nash, Australia
Prof Bruce Kirkham, United Kingdom
Prof Andrew Östör, Australia
Prof Lars Erik Kristensen, Denmark
This Lilly satellite symposium, “Pathways to better outcomes in rheumatic disease” will explore the integrated approach to improving our understanding of the impact of specific domains of chronic systemic disease, like Rheumatoid Arthritis, on the every-day-life of our patients.
The expert panel of presenters will review the recent improvements in patient management, as well as those areas that remain open to improvement, in the context of the current and emerging molecular mechanism of JAK inhibition and IL17 inhibition.
The symposium will be chaired by Prof. Peter Nash, from Australia, and will address three key areas:
- Can we improve patients’ outcomes in Rheumatoid and Psoriatic Arthritis?
Speaker: Prof. Bruce Kirkham, from UK, will explore the role of the Patient-reported Outcomes and discuss how they can influence the different treatments options in light of shared decision-making.
- JAK inhibitors: Evolving the treatment paradigm in Rheumatoid Arthritis
Speaker: Prof Andrew Östör, from Australia, will share the most up-to-date data for Baricitinib, elaborating on its use in daily practice, and discuss the placement of JAK inhibitors in the treatment algorithm for Rheumatoid Arthritis.
- Treat to target in Psoriatic Arthritis: Translating the SPIRIT programme into clinical practiceSpeaker: Prof. Lars Erik Kristensen, from Denmark, will discuss treat to target in the context of the patient with Psoriatic Arthritis and review the data from the SPIRIT trial programme in clinical practice.
The symposium will close with a panel discussion for any unanswered questions.
We hope that you find this symposium a valuable forum for discussing the impact and areas of improvement in the treatment of rheumatic disease.
|Wednesday 10 April 2019|
|1300-1305||Welcome and introduction||Prof Peter Nash|
|1305-1325||Can we improve patients’ outcomes in Rheumatoid and Psoriatic Arthritis?||Prof. Bruce Kirkham|
|1325-1345||JAK inhibitors: Evolving the treatment paradigm in Rheumatoid Arthritis||Prof Andrew Östör|
|1345-1405||Treat to target in Psoriatic Arthritis: Translating the SPIRIT programme into clinical practice||Prof Lars Erik Kristensen|
|1405-1430||Panel discussion and Q&A||All|